ENDURA
Who is this for?
Those with symptomatic COPD (have had ≥2 moderate OR ≥ 1 severe exacerbations in the past year)
Study:
This study aims to evaluate the efficacy and safety of the drug depemokimab in addition to existing triple therapy inhalers in participants with uncontrolled moderate to severe COPD.